SLC5A2 and chronic kidney disease: Uric acid concentrations are often elevated in T2DM, and SGLT2 inhibitors can increase uric acid excretion, reduce circulating uric acid, and improve cardiovascular and renal function, leading to reduction of adverse cardiovascular events and slowing the progression of chronic kidney disease [54,55].